Holen Sie sich die Stockscreener-App
52.38
2.24%
-1.20
Vorhandelsmarkt:
52.70
0.32
+0.61%
Schlusskurs vom Vortag:
$53.58
Offen:
$52.6
24-Stunden-Volumen:
3.10M
Relative Volume:
1.62
Marktkapitalisierung:
$5.05B
Einnahmen:
$3.51M
Nettoeinkommen (Verlust:
$-581.60M
KGV:
-8.0405
EPS:
-6.5145
Netto-Cashflow:
$-345.93M
1W Leistung:
+0.61%
1M Leistung:
+5.80%
6M Leistung:
-8.09%
1J Leistung:
+39.23%
1-Tages-Spanne:
$49.38
$53.94
1-Wochen-Bereich:
$49.38
$54.41
52-Wochen-Spanne:
$33.03
$78.48
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Firmenname
Crispr Therapeutics Ag
Sektor
Branche
Telefon
(617) 315-4600
Adresse
BAARERSTRASSE 14, ZUG
Compare CRSP vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
52.38 | 5.05B | 3.51M | -581.60M | -345.93M | -6.5145 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | JP Morgan | Overweight |
| 2025-02-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Hochstufung | TD Cowen | Sell → Hold |
| 2025-02-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-08-02 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-28 | Fortgesetzt | Guggenheim | Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-11 | Herabstufung | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Eingeleitet | Mizuho | Buy |
| 2023-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-04-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-08-09 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-14 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-04-21 | Hochstufung | Jefferies | Hold → Buy |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2020-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-10 | Bestätigt | Needham | Buy |
| 2020-12-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-07-28 | Bestätigt | Needham | Buy |
| 2020-07-14 | Eingeleitet | SunTrust | Buy |
| 2020-06-15 | Bestätigt | Canaccord Genuity | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Eingeleitet | Jefferies | Buy |
| 2019-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-06-10 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-14 | Eingeleitet | William Blair | Mkt Perform |
| 2019-01-28 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-22 | Herabstufung | Citigroup | Neutral → Sell |
Alle ansehen
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
Is This Millionaire-Maker Biotech Stock a Buy Right Now? - The Motley Fool
Why the market dipped but CRISPR Therapeutics AG (CRSP) gained today - MSN
CRISPR Therapeutics AG (CRSP) reports Q1 loss, lags revenue estimates - MSN
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 6.1%What's Next? - MarketBeat
CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates - TradingView
CRISPR Therapeutics Retains Buy Rating on Casgevy Momentum and 2026 Pipeline Catalysts Despite Price Target Trim to $83 - TipRanks
CRISPR Therapeutics: Pipeline Expansion and In Vivo CAR-T Platform Support Buy Rating; $80 Price Target Reiterated - TipRanks
CRISPR Therapeutics AG Q1 2026 Financial Results, Company Overview, and Key Developments - Minichart
BofA cuts CRISPR Therapeutics stock price target to $83 on valuation - Investing.com Australia
CRISPR Therapeutics Reports Q1 2026 Financial Results, Highlights CASGEVY Growth and Pipeline Progress - Minichart
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
CRISPR Therapeutics (NASDAQ:CRSP) Posts Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
CRISPR's Next Act: Pipeline Expands as CASGEVY Revenue Grows - BriefGlance
CRISPR Therapeutics AG reports results for the quarter ended March 31Earnings Summary - TradingView
CRISPR Therapeutics AG 1Q 2026: Revenue $1.458M, EPS $(1.28) — 10-Q Summary - TradingView
CRISPR Therapeutics (NASDAQ: CRSP) posts Q1 2026 loss and sells $600M converts - Stock Titan
Earnings Flash (CRSP) CRISPR Therapeutics AG Reports Q1 Revenue $1.5M, vs. FactSet Est of $6.1M - marketscreener.com
CASGEVY revenue and cash build at CRISPR Therapeutics (NASDAQ: CRSP) in Q1 2026 - Stock Titan
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - The Manila Times
CRISPR Therapeutics AG Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Assessing CRISPR Therapeutics (CRSP) Valuation After Casgevy Approval And CAR T Pipeline Progress - Sahm
CRISPR Therapeutics (CRSP) Projected to Post Quarterly Earnings on Monday - MarketBeat
Pictet Asset Management Holding SA Sells 25,129 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Is Early Casgevy Momentum Reframing CRISPR Therapeutics' (CRSP) Long-Term Profitability Narrative? - Sahm
UBS Group AG Boosts Stock Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
Trading the Move, Not the Narrative: (CRSP) Edition - Stock Traders Daily
CRSP Stock Price, Quote & Chart | CRISPR THERAPEUTICS AG (NASDAQ:CRSP) - ChartMill
ARK, Catherine Wood disclose 11.79% stake in CRSP (CRSP) - Stock Titan
CRISPR Therapeutics AG (CRSP) dips more than broader market: What you should know - MSN
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know - Yahoo Finance Singapore
CRSP Price Today: CRISPR Therapeutics AG Stock Price, Quote & Chart | MEXC - MEXC Exchange
Why the Market Dipped But CRISPR Therapeutics AG (CRSP) Gained Today - Yahoo Finance
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
CRISPR Therapeutics Hits Day Low of $48.77 Amid Price Pressure - Markets Mojo
CRISPR Therapeutics shares drop after announcing convertible notes sale - MSN
CRISPR Therapeutics AG (CRSP) Stock Drops Despite Market Gains: Important Facts to Note - MSN
CRSP Stock Firms Up As ARK Support And Needham Event Draw Traders - StocksToTrade
CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 7.5%Here's Why - MarketBeat
Why Crispr Therapeutics Stock Is Surging Again - TipRanks
CRISPR Therapeutics to Report Q1 Earnings: Is a Beat in the Cards? - TradingView
3 Biotech Stocks That Could Benefit from the Patent Cliff - MarketBeat
CRISPR Therapeutics AG (CRSP) stock slides as market rises: Facts to know before you trade - MSN
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know - MSN
Why CRISPR Therapeutics AG (CRSP) outpaced the stock market today - MSN
Assessing CRISPR Therapeutics (CRSP) Valuation After Recent Share Price Volatility - simplywall.st
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know - MSN
CRISPR Therapeutics (CRSP) Stock Drops 11% – Bad Earnings, a Free Rival Therapy, and a CEO Selling - MEXC Exchange
Finanzdaten der Crispr Therapeutics Ag-Aktie (CRSP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):